BRAF-Mutated Melanoma Journey in Latin America: Expert Recommendations From Diagnosis to Treatment.
Cancer Control
; 31: 10732748241251572, 2024.
Article
in En
| MEDLINE
| ID: mdl-38751033
ABSTRACT
OBJECTIVES:
⢠Gather a panel of Latin American experts in testing and treating BRAF-melanoma. ⢠Describe the current landscape of BRAF-mutated melanoma in Latin America. ⢠Outline the current gaps in testing and recommend improvements for testing and treating BRAF-mutated melanoma in the region.INTRODUCTION:
Melanoma prevalence in Latin America is lower than in high- and middle-income countries. However, recent data indicate that the region's incidence and mortality are rising, with more stage IV patients being diagnosed. According to international clinical practice guidelines, conducting BRAF-mutation testing in patients with stage III or stage IV melanoma and high-risk resected disease is imperative. Still, BRAF-mutation testing and targeted therapies are inconsistently available in the region.METHODS:
Americas Health Foundation convened a meeting of Latin American experts on BRAF-mutated melanoma to develop guidelines and recommendations for diagnosis through treatment. RESULTS ANDCONCLUSIONS:
Some recommendations for improving diagnostics through improving access and reducing the cost of BRAF-mutation testing, enhancing efficiency in pathology laboratories, and creating country-specific local guidelines. The panel also gave treatment recommendations for neo-adjuvant therapy, adjuvant therapy, and therapy for patients with metastatic disease in Latin America.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Proto-Oncogene Proteins B-raf
/
Melanoma
/
Mutation
Limits:
Humans
Language:
En
Journal:
Cancer Control
Journal subject:
NEOPLASIAS
Year:
2024
Document type:
Article
Affiliation country:
Colombia
Country of publication:
United States